To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Abroad (travel likely)RecruitingPHASE1
Conditions
Melanoma Stage III · Melanoma Stage IV · Melanoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Department of Oncology, Herlev, Denmark
Contact: Study coordinator (Inge Marie Svane, Professor) · inge.marie.svane@regionh.dk · 004538683131Contact: Study coordinator (Cecilie Dam Vestergaard, Medical doctor) · cecilie.dam.vestergaard@regionh.dk · 004538686589Contact: Principal Investigator (Cecilie Dam Vestergaard, Medical Doctor)Department of Oncology, Herlev, Denmark
Contact: Study coordinator (Inge Marie Svane, Professor) · inge.marie.svane@regionh.dk · 004538683131Contact: Study coordinator (Cecilie Dam Vestergaard, Medical doctor) · cecilie.dam.vestergaard@regionh.dk
Study leads
Inge Marie Svane, Prof., M.D.
Study Director
Study Director, CCIT-DK, Depth of Oncology, Herlev Hospital
Cecilie D Vestergaard, M.D.
Principal Investigator
Clinical research assistant, CCIT-DK, Depth of Oncology, Herlev Hospital